<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Turk J Haematol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Turk J Haematol</journal-id>
      <journal-id journal-id-type="publisher-id">TJH</journal-id>
      <journal-title-group>
        <journal-title>Turkish Journal of Hematology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1300-7777</issn>
      <issn pub-type="epub">1308-5263</issn>
      <publisher>
        <publisher-name>Galenos Publishing</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26376833</article-id>
      <article-id pub-id-type="pmc">4805328</article-id>
      <article-id pub-id-type="doi">10.4274/tjh.2015.0164</article-id>
      <article-id pub-id-type="publisher-id">1575</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Downgraded Lymphoma: B-Chronic Lymphocytic Leukemia in a Known Case of Diffuse Large B-Cell Lymphoma - De Novo Occurrence or Transformation</article-title>
        <trans-title-group xml:lang="tr">
          <trans-title>Geriletilmi&#x15F; Lenfoma: Diff&#xFC;z B&#xFC;y&#xFC;k B H&#xFC;creli Lenfoma Oldu&#x11F;u Bilinen Bir Olguda B-Kronik Lenfositik L&#xF6;semi- De Novo Olu&#x15F;um veya D&#xF6;n&#xFC;&#x15F;&#xFC;m</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Gajendra</surname>
            <given-names>Smeeta</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="corresp" rid="COR1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jha</surname>
            <given-names>Bhawna</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Goel</surname>
            <given-names>Shalini</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sahni</surname>
            <given-names>Tushar</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dorwal</surname>
            <given-names>Pranav</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sachdev</surname>
            <given-names>Ritesh</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>
Medanta-The Medicity, Department of Pathology and Laboratory Medicine, Gurgaon, India
</aff>
      <author-notes>
        <corresp id="COR1">* Address for Correspondence: Medanta-The Medicity, Department of Pathology and Laboratory Medicine, Gurgaon, India Phone: 0901 359 08 75 E-mail: <email>drsmeeta@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>12</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>3</day>
        <month>12</month>
        <year>2015</year>
      </pub-date>
      <volume>32</volume>
      <issue>4</issue>
      <fpage>371</fpage>
      <lpage>372</lpage>
      <history>
        <date date-type="received">
          <day>23</day>
          <month>4</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>6</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Turkish Journal of Hematology, Published by Galenos Publishing.&#xD;
</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <kwd-group>
        <kwd>Diffuse large B-cell lymphoma</kwd>
        <kwd>Chronic lymphocytic leukemia</kwd>
        <kwd>Downgraded lymphoma</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>TO THE EDITOR</title>
      <p>Low-grade indolent lymphomas can be transformed into high-grade aggressive lymphomas [<xref rid="ref1" ref-type="bibr">1</xref>,<xref rid="ref2" ref-type="bibr">2</xref>,<xref rid="ref3" ref-type="bibr">3</xref>,<xref rid="ref4" ref-type="bibr">4</xref>]. Very few cases of transformation of high/intermediate-grade lymphoma to low-grade lymphoma have been reported in the literature [<xref rid="ref5" ref-type="bibr">5</xref>,<xref rid="ref6" ref-type="bibr">6</xref>]. This may arise through transformation of the original clone or may represent a new neoplasm resulting from additional genetic mutations that alter the growth rate, growth pattern, and sensitivity to treatment.</p>
      <p> A 57-year-old male diagnosed with diffuse large B-cell lymphoma (DLBCL) (non-germinal center B-cell type) in 2002 completed 6 cycles of CHOP followed by radiotherapy. In 2006, 18F- fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) showed no active disease. In 2007 there was recurrence in the left obturator and external iliac nodes. Lymph node biopsy done outside our facility showed CD20+ B-cell lymphoma. The patient was advised to undergo intensive chemotherapy, but was lost to follow-up. In 2010, the patient came to our hospital with bilateral firm non-tender inguinal and right axillary lymphadenopathy without any organomegaly. 18F PET/CT revealed heterogeneous uptake in the left paraaortic, retrocaval, precaval, and bilateral internal iliac nodes. A previous diagnostic lymph node biopsy was reviewed, showing diffuse infiltration of large atypical cells, positive for CD20, CD30, MUM1, and Bcl2 with a Ki67 index of 80% and negative for CD3, CD5, and CD10, which was consistent with DLBCL (<xref ref-type="fig" rid="f1">Figure 1A</xref>). Biopsy of the paraaortic mass revealed sheets of small lymphoid cells, which were positive for CD20, CD5, and CD23 and negative for CD3 and cyclin D1 with a low Ki67 index, suggestive of small-cell lymphoma (<xref ref-type="fig" rid="f1">Figure 1B</xref>). 18F PET-CT was repeated after 1 year, showing multiple FDG-avid cervical, supraclavicular, mediastinal, axillary, abdominal, and pelvic lymphadenopathies (<xref ref-type="fig" rid="f1">Figure 1C</xref>). After 10 months, hemoglobin was 90 g/L, total leukocyte count was 21.1x109/L, and platelet count was 40x109/L. Peripheral blood smear showed 84% abnormal lymphoid cells, which were immunopositive for CD19, CD5, CD23, CD22 (dim), CD200, and CD20 with lambda light chain restriction and negative for CD10, FMC7, CD38, IgM, and CD103, confirming the diagnosis of chronic lymphocytic leukemia (CLL) (<xref ref-type="fig" rid="f1">Figure 1D</xref>). The patient was started on a fludarabine, cyclophosphamide, and rituximab (FCR) regimen. After 6 cycles of FCR, he was in complete remission and was started on rituximab maintenance therapy.</p>
      <p>The phenomenon of high- or intermediate-grade non-Hodgkin lymphoma recurring as a low-grade lymphoma is an uncommon form of transformation known as &#x201C;downgraded&#x201D; lymphoma. This downgrading may be due to: 1) recurrence of a low-grade lymphoma that was present as a minor component of the initial lymphoma or in a site not biopsied, or 2) development of a second lymphoma resulting from chemotherapy and/or an intrinsic propensity for lymphoma development in the patient [5,6]. Relapse in DLBCL mainly occurs in the first 2 to 3 years, while late relapses after 5 years are rare, occurring in 3.6% of cases. Patients with DLBCL relapse usually have the same histology. However, relapse as indolent lymphoma following initial DLBCL may occur in about 17% of cases, predominantly as follicular lymphoma or rarely as nodal marginal zone lymphoma or as extranodal mucosa-associated lymphoid tissue lymphoma [<xref rid="ref7" ref-type="bibr">7</xref>]. Histopathological examination including extensive immunohistochemistry should be done, not only when transformation is clinically suspected but also at each recurrence because the disease can recur as indolent lymphoma and an accurate histologic diagnosis will contribute to a better understanding of the pathogenesis of transformation and the start of prompt therapy to improve the survival of the patients.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="FN3" fn-type="con">
        <p><bold>Concept:</bold> Smeeta Gajendra, Bhawna Jha, Shalini Goel, Tushar Sahni, Pranav Dorwal, Ritesh Sachdev, <bold>Design:</bold> Smeeta Gajendra, Bhawna Jha, Shalini Goel, Tushar Sahni, Pranav Dorwal, Ritesh Sachdev, <bold>Data Collection or Processing:</bold> Smeeta Gajendra, Bhawna Jha, Shalini Goel, Pranav Dorwal, Ritesh Sachdev, <bold>Analysis or Interpretation:</bold> Smeeta Gajendra, Bhawna Jha, Tushar Sahni, Ritesh Sachdev, <bold>Literature Search:</bold> Smeeta Gajendra, Ritesh Sachdev, <bold>Writing:</bold> Smeeta Gajendra.</p>
      </fn>
      <fn id="FN1" fn-type="conflict">
        <p><bold>Conflict of Interest:</bold> The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Tsimberidou</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Keating</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Richter syndrome: biology, incidence, and therapeutic strategies</article-title>
          <source>Cancer</source>
          <year>2005</year>
          <volume>103</volume>
          <fpage>216</fpage>
          <lpage>228</lpage>
          <pub-id pub-id-type="pmid">15578683</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Rossi</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Cerri</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Capello</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Deambrogi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Zucchetto</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>De Paoli</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Cresta</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rasi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Spina</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Franceschetti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lunghi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vendramin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bomben</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ramponi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Monga</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Conconi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Magnani</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gattei</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Gaidano</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome</article-title>
          <source>Br J Haematol</source>
          <year>2008</year>
          <volume>142</volume>
          <fpage>202</fpage>
          <lpage>215</lpage>
          <pub-id pub-id-type="pmid">18492108</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Montoto</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fitzgibbon</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Transformation of indolent B-cell lymphomas</article-title>
          <source>J Clin Oncol</source>
          <year>2011</year>
          <volume>29</volume>
          <fpage>1827</fpage>
          <lpage>1834</lpage>
          <pub-id pub-id-type="pmid">21483014</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mansoor</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bueso-Ramos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hao</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lai</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Medeiros</surname>
              <given-names>LJ</given-names>
            </name>
          </person-group>
          <article-title>Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenstr&#xF6;m macroglobulinemia. Clinicopathologic features of 12 cases</article-title>
          <source>Am J Clin Pathol</source>
          <year>2003</year>
          <volume>120</volume>
          <fpage>246</fpage>
          <lpage>253</lpage>
          <pub-id pub-id-type="pmid">12931555</pub-id>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Kerrigan</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Foucar</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dressler</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>High-grade non-Hodgkin lymphoma relapsing as low-grade follicular lymphoma: so-called downgraded lymphoma</article-title>
          <source>Am J Hematol</source>
          <year>1989</year>
          <volume>30</volume>
          <fpage>36</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="pmid">2535611</pub-id>
        </element-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Ogata</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Setoguchi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tahara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Downgraded non-Hodgkin&#x2019;s lymphoma in the neck occurring as a secondary malignancy</article-title>
          <source>ORL J Otorhinolaryngol Relat Spec</source>
          <year>1998</year>
          <volume>60</volume>
          <fpage>295</fpage>
          <lpage>300</lpage>
          <pub-id pub-id-type="pmid">9693308</pub-id>
        </element-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <element-citation publication-type="journal" publication-format="online">
          <person-group person-group-type="author">
            <name>
              <surname>Larouche</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Chassagne-Cl&#xE9;ment</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ffrench</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Callet-Bauchu</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sebban</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ghesqui&#xE8;res</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Broussais-Guillaumot</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Salles</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Coiffier</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome</article-title>
          <source>J Clin Oncol</source>
          <year>2010</year>
          <volume>28</volume>
          <fpage>2094</fpage>
          <lpage>2100</lpage>
          <pub-id pub-id-type="pmid">20308668</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="f1" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <title>A) Lymph node biopsy showing diffuse infiltration of large atypical cells with prominent nucleoli and vesicular chromatin, which were positive for CD20, CD30, and MUM1 with a Ki67 index of 80%. B) Biopsy from paraaortic mass showing small-sized neoplastic cells with scant cytoplasm, hyperchromatic nuclei, and clumped chromatin arranged in sheets, which were positive for CD20 and CD5 and negative for cyclin D1 with a low Ki67 index. C) 18F-FDG PET-CT showing multiple cervical, supraclavicular, mediastinal, axillary, abdominal, and pelvic lymphadenopathies with gross splenomegaly. D) Immunophenotyping of peripheral blood smear showing 84% abnormal lymphoid cells, which were positive for CD19, CD5, CD23, CD22 (dim), and CD200 with lambda light chain restriction and negative for FMC7.</title>
      </caption>
      <graphic xlink:href="TJH-32-371-g1"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
